Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RVMD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRevolution Medicines reports Phase 3 pancreatic cancer trial success, raises $2.2B
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Daraxonrasib showed median overall survival of 13.2 months vs. 6.7 months for chemotherapy in Phase 3 pancreatic cancer trial (hazard ratio 0.40, p<0.0001); company plans regulatory submissions including FDA filing.
Exhibit 99.1 view on EDGAR → -
high
Raised $2.225 billion gross proceeds through concurrent offerings: $1.725 billion in common stock and $500 million in 0.50% convertible notes due 2033, receiving $2.1 billion net in April 2026.
Exhibit 99.1 view on EDGAR → -
high
Q1 2026 net loss of $453.8 million, more than double the $213.4 million loss in Q1 2025, driven by higher R&D expenses ($344.0M vs. $205.7M) and G&A expenses ($101.3M vs. $35.0M).
Exhibit 99.1 view on EDGAR → -
medium
Modified equity compensation program to add retirement benefits, accelerating $44.6 million in Q1 2026 stock-based compensation expense and raising full-year 2026 guidance by ~$80 million to $260-up to $280 million.
Exhibit 99.1 view on EDGAR → -
medium
Raised full-year 2026 GAAP operating expense guidance to $1.7-$1.8 billion, primarily reflecting increased stock-based compensation from the equity program modification.
Exhibit 99.1 view on EDGAR →
Summary
Revolution Medicines delivered a transformative clinical milestone with positive Phase 3 results for daraxonrasib in second-line metastatic pancreatic cancer. The drug nearly doubled median overall survival compared to chemotherapy (13.2 months vs. 6.7 months), with highly significant statistical results.
The company plans regulatory submissions including an FDA filing, positioning daraxonrasib as a potential first-in-class RAS inhibitor for this difficult-to-treat cancer. The company raised $2.2 billion in concurrent equity and convertible debt offerings in April 2026, significantly strengthening its balance sheet to fund commercialization and ongoing clinical programs.
This capital raise, combined with the Phase 3 success, positions Revolution Medicines to advance toward potential product approval and launch. Operating expenses are rising sharply as the company scales for commercialization. Q1 2026 net loss more than doubled year-over-year to $453.8 million, driven by expanded R&D and G&A spending. A new equity compensation retirement benefit added $44.6 million in accelerated expense in Q1 and will increase full-year 2026 stock-based compensation by approximately $80 million. Full-year operating expense guidance increased to $1.7-$1.8 billion. The burn rate is substantial but reflects the company's transition from pure development to preparing for commercial launch.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 2, 2026 · How we verify